Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 28 February 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration announced on 28 February that it is implementing "important safety changes to the labeling" of some of the most popular statin drugs on the market, including Lipitor, Crestor and Zocor.
FDA announced four changes to the labeling for the statin products:
"[T]hese medications continue to provide an important health benefit of lowering cholesterol," said Mary Parks, M.D., director for the Division of Metabolism and Endocrinology Products in the Office of Drug Evaluation II in FDA's Center for Drug Evaluation and Research.
Statin products are used to lower low-density lipoprotein cholesterol when combined with diet and exercise.
FDA announces safety changes in labeling for some cholesterol-lowering drugs
Tags: Statin, Pharmaceuticals, Latest News, Warning
Regulatory Focus newsletters
All the biggest regulatory news and happenings.